These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21306626)

  • 41. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
    Stefanovics EA; Krystal JH; Rosenheck RA
    Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
    Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
    Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia.
    Levine SZ; Leucht S
    Schizophr Res; 2012 Nov; 141(2-3):168-72. PubMed ID: 22995933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Leucht S; Barabássy Á; Laszlovszky I; Szatmári B; Acsai K; Szalai E; Harsányi J; Earley W; Németh G
    Neuropsychopharmacology; 2019 Aug; 44(9):1589-1596. PubMed ID: 30836381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.
    Samara MT; Leucht C; Leeflang MM; Anghelescu IG; Chung YC; Crespo-Facorro B; Elkis H; Hatta K; Giegling I; Kane JM; Kayo M; Lambert M; Lin CH; Möller HJ; Pelayo-Terán JM; Riedel M; Rujescu D; Schimmelmann BG; Serretti A; Correll CU; Leucht S
    Am J Psychiatry; 2015 Jul; 172(7):617-29. PubMed ID: 26046338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
    Potkin SG; Phiri P; Szegedi A; Zhao J; Alphs L; Cazorla P
    Schizophr Res; 2013 Nov; 150(2-3):442-9. PubMed ID: 24075603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
    Leucht S; Zhao J
    J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
    Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC
    Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
    Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R
    Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.